Bioventix (LSE:BVXP) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Bioventix Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bioventix's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bioventix could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Bioventix's Cash-to-Debt or its related term are showing as below:

LSE:BVXP' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Bioventix's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

LSE:BVXP's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs LSE:BVXP: No Debt

Bioventix Cash-to-Debt Historical Data

The historical data trend for Bioventix's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bioventix Cash-to-Debt Chart

Bioventix Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Bioventix Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Bioventix's Cash-to-Debt

For the Biotechnology subindustry, Bioventix's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioventix's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioventix's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bioventix's Cash-to-Debt falls into.

Bioventix Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bioventix's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Bioventix had no debt ⁽¹⁾.

Bioventix's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Bioventix had no debt ⁽¹⁾.

Bioventix (LSE:BVXP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bioventix Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bioventix's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioventix (LSE:BVXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BVXP.GB:UK 51B:Germany

Address

East Street, 7 Romans Business Park, Farnham, Surrey, GBR, GU9 7SX

Website

http://www.bioventix.com

Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.

Bioventix (LSE:BVXP) Headlines

No Headlines

Bioventix (LSE:BVXP) Cash-to-Debt : No Debt (1) (As of Dec. 2023)